PREVIEW | Conference Schedule
WelcomeInternational Congress on Genitourinary Malignancies - Daniel P. Petrylak, MD
Prostate Cancer
Moderated by Daniel P. Petrylak, MD, and Leonard G. Gomella, MD, FACS
Biomarkers in Prostate Cancer - Leonard G. Gomella, MD, FACS
The PSA Screening Controversy: Re-analysis of ERSPC and PLCO Trial Data - E. David Crawford, MD
Challenging Case Debates: Localized Prostate Cancer - Daniel P. Petrylak, MD
Current and Emerging Standards in Radiation Therapy for Prostate Cancer - James B. Yu, MD, MHS
Novel Hormonal Agents for Advanced Castration-Resistant Prostate Cancer - Robert Dreicer, MD, MS, MACP, FASCO
Early Use of Systemic Therapy: Abiraterone Versus Docetaxel for Hormone-Sensitive Prostate Cancer - Celestia S. Higano, MD, FACP
Immune Therapy for Advanced Prostate Cancer - Susan Slovin, MD, PhD
When to Use Isotope Therapy for Advanced Prostate Cancer - Richard G. Stock, MD
DNA Damage Repair: Implications for Next Generation Sequencing and Therapeutic Development in Prostate Cancer - Maha H Hussain, MD, FACP, FASCO
Challenging Case Debates: Best Practices for Advanced Disease - Leonard G. Gomella, MD, FACS
Renal Cell
Moderated by Daniel P. Petrylak, MD
Targeted Therapies in Renal Cell Carcinoma - David I Quinn, MBBS, PhD, FRACP, FACP
Immunotherapy in Renal Cell Carcinoma - Mario Sznol, MD
Evolving Therapeutic Strategies in Renal Cell Carcinoma: Neoadjuvant and Adjuvant Approaches - David M Nanus, MD
Challenging Case Debates: Highlight on Therapeutic Sequencing and Adverse Event Management in Renal Cell Carcinoma - Daniel P. Petrylak, MD
Urothelial Carcinoma
Moderated by Leonard G. Gomella, MD, FACS
Genomics, Genetics and Prostate Cancer - Leonard G. Gomella, MD, FACS
Management of Early Bladder Cancer - Daniel P. Petrylak, MD
Immunotherapy and Other Novel Treatments for Metastatic Urothelial Carcinoma - Daniel P. Petrylak, MD
Challenging Case Debates: Best Practices for Bladder Cancer - Daniel P. Petrylak, MD
